drugset / Trial / NCT01324401

Oral Peanut Immunotherapy

NCT01324401

Completed 30 enrolled Massachusetts General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions. Effective oral immunotherapy would benefit patients by reducing the likelihood that they will have life-threatening accidental allergic reactions. This research study is being done to develop an effective oral immunotherapy treatment for patients with peanut allergy.

Timeline

Start
2011-03
Primary completion
2016-05
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Peanut Flour Protein / enzyme biologic 4000 mg Oral

Indications